Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

- PMLiVE

EC approves Atara and Pierre Fabre’s Ebvallo as monotherapy for Epstein-Barr patients

The approval is for adults and those over two years old with relapsed or refractory EBV+PTLD

- PMLiVE

Kite announces acquisition of Tmunity Therapeutics in latest agreement

The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform

- PMLiVE

How and when should we innovate our strategies to deliver competitive change?

Understanding the five mistakes to avoid in order to ensure brand success

- PMLiVE

The role of medical communications in building credibility for healthtech

By Sarah Funderburk

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

MHRA set to receive nearly £1m from BEIS’ Regulator’s Pioneer Fund

Funding will aid three projects aiming to harness digital, data and scientific regulatory innovation

- PMLiVE

WHO joins calls for equitable access to healthcare products ahead of future pandemics

The WHO, WIPO and WTO gathered at the Joint Technical Symposium on 16 December

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease

Sharpening the focus to ‘treating the patient, not the disease’ can lead to a paradigm shift in outcomes

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer

Approximately 136,000 cases of gastric cancer are diagnosed annually in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links